Illumina logo

IlluminaNASDAQ: ILMN

Profile

Sector:

Healthcare

Country:

United States

IPO:

28 July 2000

Next earnings report:

07 February 2025

Last dividends:

N/A

Next dividends:

N/A
$20.81 B
-67%vs. 3y high
96%vs. sector
-vs. 3y high
-vs. sector
-34%vs. 3y high
92%vs. sector
-66%vs. 3y high
60%vs. sector

Price

regular market | 2 min ago
$131.22-$3.78(-2.80%)

Dividend

No data over the past 3 years
$1.08 B$1.07 B
$1.08 B$705.00 M

Analysts recommendations

Institutional Ownership

ILMN Latest News

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)
seekingalpha.com20 November 2024 Sentiment: -

Illumina, Inc. (NASDAQ:ILMN ) Wolfe Research 2024 Healthcare Conference Call November 20, 2024 9:20 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Doug Schenkel All right. Good morning, everybody.

Illumina announces expansion of TruSight Oncology portfolio
prnewswire.com19 November 2024 Sentiment: POSITIVE

The latest solution to enable comprehensive genomic profiling of tumors will be presented at the  annual meeting of the Association of Molecular Pathology Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling SAN DIEGO , Nov. 19, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025.

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
zacks.com11 November 2024 Sentiment: POSITIVE

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Illumina: Q3 Confirms Improving Fundamentals
seekingalpha.com05 November 2024 Sentiment: POSITIVE

Illumina is the leader in the undisputed Next Generation Sequencing market. Grail divestment is behind, enabling a margin expansion and fueling a more robust cash flow generation. The stock was down after hours, as much good news has been priced in the recent rally.

ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket
zacks.com05 November 2024 Sentiment: POSITIVE

Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.

Illumina (ILMN) Tops Q3 Earnings and Revenue Estimates
zacks.com04 November 2024 Sentiment: POSITIVE

Illumina (ILMN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.33 per share a year ago.

EARNINGS ALERT: ILMN
youtube.com04 November 2024 Sentiment: POSITIVE

Illumina (ILMN) is trading down guiding a 3% decline in revenue. George Tsilis believes the company is still notable despite the market's reaction.

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024
prnewswire.com04 November 2024 Sentiment: NEUTRAL

Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024 Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024 Lowered fiscal year 2024 Core Illumina revenue guidance to decline ~3% from fiscal year 2023; expect Q4 2024 Core Illumina revenue of approximately $1.07 billion Raised fiscal year 2024 Core Illumina non-GAAP operating margin guidance to a range of 21% to 21.5% Raised fiscal year 2024 Core Illumina non-GAAP diluted EPS guidance to a range of $4.05 to $4.15 SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2024. The financial results for YTD 2024 and Q3 2023 and YTD 2023 include the financial results for GRAIL which was spun off on June 24, 2024.

Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting
prnewswire.com31 October 2024 Sentiment: POSITIVE

New, groundbreaking technology delivers Illumina's most comprehensive genome yet ; early results from Broad Clinical Labs demonstrate a highly simplified workflow , ultra-long phasing, high-resolution insights into complex genomic variation, and enhanced long-range information   Illumina and customers will also showcase new details on complete proteomics solution and latest data on Fluent single-cell technology SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will present updates on several key innovations in whole-genome sequencing, proteomics, and single-cell technology at the American Society of Human Genetics (ASHG) Annual Meeting next week in Denver. The latest details will be presented alongside new data from key opinion leaders in next-generation sequencing (NGS), illustrating the potential impact of Illumina's emerging innovations.

Illumina's Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?
zacks.com24 October 2024 Sentiment: POSITIVE

In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.

What type of business is Illumina?

Illumina, Inc. is a global leader in the field of sequencing (technology for reading genetic code) and array-based solutions for genetic and genomic analysis. This area of activity is relatively new and developing. Illumina, Inc. is the author of next-generation sequencing technologies. Illumina, Inc. was founded in 1998. The company's headquarters is located in San Diego, California. Its products and solutions are designed for use in the fields of life sciences, diagnostics, agriculture, pharmaceuticals, and consumer genomics. Illumina, Inc.'s clients include leading genomics research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

What sector is Illumina in?

Illumina is in the Healthcare sector

What industry is Illumina in?

Illumina is in the Diagnostics & Research industry

What country is Illumina from?

Illumina is headquartered in United States

When did Illumina go public?

Illumina initial public offering (IPO) was on 28 July 2000

What is Illumina website?

https://www.illumina.com

Is Illumina in the S&P 500?

No, Illumina is not included in the S&P 500 index

Is Illumina in the NASDAQ 100?

Yes, Illumina is included in the NASDAQ 100 index

Is Illumina in the Dow Jones?

No, Illumina is not included in the Dow Jones index

When was Illumina the previous earnings report?

No data

When does Illumina earnings report?

The next expected earnings date for Illumina is 07 February 2025